A Study of XMT-1660 in Solid Tumors
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with XMT-1660 during the first cycle of treatment (Dose Escalation)
Timeframe: 17 months
Incidence of adverse events (Dose Escalation and Dose Expansion)
Timeframe: 3 years
Objective Response Rate (ORR) (Dose Expansion)
Timeframe: approximately 3 years